Spero Therapeutics Inc. (SPRO)
NASDAQ: SPRO
· Real-Time Price · USD
1.89
-0.09 (-4.55%)
At close: Aug 15, 2025, 12:53 PM
-4.55% (1D)
| Bid | 1.84 |
| Market Cap | 106.36M |
| Revenue (ttm) | 34.72M |
| Net Income (ttm) | -70.63M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -1.93 |
| Forward PE | 4.56 |
| Analyst | Hold |
| Ask | 1.93 |
| Volume | 742,570 |
| Avg. Volume (20D) | 4,600,548 |
| Open | 1.95 |
| Previous Close | 1.98 |
| Day's Range | 1.85 - 1.96 |
| 52-Week Range | 0.51 - 3.22 |
| Beta | 1.39 |
About SPRO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SPRO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SPRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 days ago
-17.8%
Spero Therapeutics shares are trading lower follow...
Unlock content with
Pro Subscription
2 weeks ago
-1.36%
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
2 months ago · seekingalpha.com
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsBased on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a licen...
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO)Squarepoint Ops LLC bought a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and ...
